About Semaphorin-4B
Semaphorin-4B (SEMA4B) is a protein
from Homo sapiens identified by UniProt accession
Q9NPR2, 837 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | Semaphorin-4B |
|---|
| UniProt accession | Q9NPR2 |
|---|
| Gene | SEMA4B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 837 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NPR2-F1 | alphafold | PREDICTED | 81.56 | — |
Amino-acid sequence (837 residues)
MLRTAMGLRS WLAAPWGALP PRPPLLLLLL LLLLLQPPPP TWALSPRISL PLGSEERPFL RFEAEHISNY TALLLSRDGR TLYVGAREAL FALSSNLSFL PGGEYQELLW GADAEKKQQC SFKGKDPQRD CQNYIKILLP LSGSHLFTCG TAAFSPMCTY INMENFTLAR DEKGNVLLED GKGRCPFDPN FKSTALVVDG ELYTGTVSSF QGNDPAISRS QSLRPTKTES SLNWLQDPAF VASAYIPESL GSLQGDDDKI YFFFSETGQE FEFFENTIVS RIARICKGDE GGERVLQQRW TSFLKAQLLC SRPDDGFPFN VLQDVFTLSP SPQDWRDTLF YGVFTSQWHR GTTEGSAVCV FTMKDVQRVF SGLYKEVNRE TQQWYTVTHP VPTPRPGACI TNSARERKIN SSLQLPDRVL NFLKDHFLMD GQVRSRMLLL QPQARYQRVA VHRVPGLHHT YDVLFLGTGD GRLHKAVSVG PRVHIIEELQ IFSSGQPVQN LLLDTHRGLL YAASHSGVVQ VPMANCSLYR SCGDCLLARD PYCAWSGSSC KHVSLYQPQL ATRPWIQDIE GASAKDLCSA SSVVSPSFVP TGEKPCEQVQ FQPNTVNTLA CPLLSNLATR LWLRNGAPVN ASASCHVLPT GDLLLVGTQQ LGEFQCWSLE EGFQQLVASY CPEVVEDGVA DQTDEGGSVP VIISTSRVSA PAGGKASWGA DRSYWKEFLV MCTLFVLAVL LPVLFLLYRH RNSMKVFLKQ GECASVHPKT CPVVLPPETR PLNGLGPPST PLDHRGYQSL SDSPPGSRVF TESEKRPLSI QDSFVEVSPV CPRPRVRLGS EIRDSVV
Explore Semaphorin-4B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets